Return to homepagePandemic Pact

COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) VARIANT TESTING

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-P00005-759102000004-2

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $6,477,336

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    SALIBA KATY

  • Research Location

    United States of America

  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) variant testing provides support for analysis of SARS-CoV-2 genome sequences from specimens collected in COVID-19 therapeutic and observational trials for genetic variants that could impact diagnostics, therapeutics, vaccine efficacy, and disease severity. COVID SAVE provides support for the analysis of the impact of SARS-CoV-2 variants on disease severity in animal models and in vitro neutralization assays. Additionally, COVID SAVE variant testing allows analysis of the evolution of SARS-CoV-2 and identification of future variants with potential public health impacts.